RYDAPT is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard.
Adverse events should also be reported to Novartis via email@example.com or
online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370
or by email at firstname.lastname@example.org